“Strategic Responses to Cultural Quotas: Evidence from French Radio” (with Dandan Niu)
“Estimating the Effects on Mortality Rates of Cancer Drug Innovation” (with Pierre Dubois)
“The More We Die, The More We Sell? A Simple Test of the Home-Market Effect” (with Arnaud Costinot, Dave Donaldson, and Heidi Williams)
“Experts and Conflicts of Interest: Evidence from FDA Advisory Committees,” with Fanny Camara.
“Intellectual Property Rights and Access to Innovation: Evidence from TRIPS,” with Yi Qian.
“Strategic Interaction among Governments in the Provision of a Global Public Good” (2017), with David Ridley and Su Zhang, Journal of Public Economics, forthcoming.
“Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets” (2017), Review of Industrial Organization, forthcoming.
“Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs” (2017), with Heidi L. Williams, American Economic Review Papers & Proceedings, 107(5):486-490.
“Competition Law, Intellectual Property, and the Pharmaceutical Sector” (2016), Antitrust Law Journal 81(1).
“Competition and the Efficiency of Markets for Technology” (2015), with Marie-Laure Allain and Emeric Henry, Management Science 62(4), 1000 - 1019.
“Intellectual Property Protection and the Geography of Trade” (2013), with Mercedes Delgado and Anita McGahan, Journal of Industrial Economics 61(3): 733-762.
“Alliances, Mergers and Acquisitions,” with Henry Grabowski, in Anthony J. Culyer, editor, Elsevier Encyclopedia of Health Economics (Elsevier, 2013).
“Investments in Pharmaceuticals Before and After TRIPS” (2012), with Anita McGahan, Review of Economics and Statistics, 94(4): 1157-1172.
“Markets for Pharmaceutical Products,” with Fiona Scott Morton, Handbook of Health Economics Vol. 2 (edited by Mark Pauly, Thomas McGuire and Pedro Pita Barros), 2012.
“Mergers, Acquisitions, and Alliances” with Henry Grabowski, Chapter 18 in Handbook of the Economics of the BioPharmaceutical Industry (edited by Patricia Danzon and Sean Nicholson), 2012.
“Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act,'' with Henry Grabowski, Richard Mortimer, Genia Long and Noam Kirson, November 2011, Health Affairs 30:2157-2166.
with Till Barnighausen, Joshua Salomon and Brenda Waning, September 2011, Health Policy and Planning, doi: 10.1093/heapol/czr058.
“Strategic Responses to Parallel Trade," 2011, B.E. Journal of Economic Analysis and Policy: Advances, Vol. 11 : Iss. 2 (Advances), Article 2.
“Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets" (with Brenda Waning, Ellen Diedrichsen, Lyne Soucy, Jenny Hochstadt, Till Barnighausen and Suerie Moon), Globalization and Health 2010, 6:9.
“Parallel Trade in Pharmaceuticals: Firm Responses and Competition Policy," Chapter 13 in International Antitrust Law & Policy: Fordham Competition Law 2009, edited by Barry Hawk (Juris Publishing, New York, 2009).
“Comparative advantages of push and pull incentives for technology development: lessons for neglected diseases" with Cheri Grace, in Global Forum Update on Research for Health Volume 6, 2009.
“Does Re-importation Reduce Price Differences for Prescription Drugs? Lessons from the European Union," with Jennifer Allsbrook and Kevin Schulman, Health Services Research August 2008, 43(4), 1308-1324.
“Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity," with Henry Grabowski, in The Economics of Corporate Governance and Mergers, edited by Klaus Peter Gugler and B. Burcin Yurtoglu (Cheltenham, UK: Edward Elgar Publishing, 2008).
“Would Greater Price Transparency and Uniformity Benefit Poor Patients?" with David Ridley, Health Affairs Sept/Oct 2007, 26(5), 1384-1391.
“Generic Competition and Market Exclusivity Periods in Pharmaceuticals," with Henry Grabowski, Managerial and Decision Economics June-August 2007, 28(4-5), 491-502.
"Pharmaceutical Price Controls and Entry Strategies," Review of Economics and Statistics February 2007, 89(1), 88-99
"The Role of Firm Characteristics in Pharmaceutical Product Launches," RAND Journal of Economics Autumn 2006, 37(3), 602-618.
“Objective and Self-Reported Work Performance Measures: A Comparative Analysis," with Glenn Pransky, Ernst Berndt, Stan Finkelstein, Joan Mackell, and Dan Tortorice (2006), International Journal of Productivity & Performance Management 55(5), 390-399.
"Surviving the Gales of Creative Destruction: The Determinants of Product Turnover," with John M. de Figueiredo (2006), Strategic Management Journal 27(3), 241-264.
"Public & Private Spillovers, Location, and the Productivity of Pharmaceutical Research," with Jeff Furman, Iain Cockburn, and Rebecca Henderson, Annales d'Economie et Statistique 2005, 79/80, 165-188.
“Product Launch Decisions by Dominant and Fringe Firms," with John M. de Figueiredo, Best Paper Proceedings of the Academy of Management, 2005.
"Does Locale Affect R&D Productivity? The Case of Pharmaceuticals," Federal Reserve Bank of San Francisco Economic Letter, Nov. 13, 2004.
"The Long Shadow of Patent Expiration: Do Rx to OTC Switches Provide an Afterlife?" with Ernst R. Berndt and Davina Ling, Scanner Data and Price Indexes, edited by Robert Feenstra and Matthew Shapiro (Chicago: University of Chicago Press, 2003), 229-267.
"Deregulating Direct-to-consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-counter Sales" with Ernst R. Berndt and Davina Ling (2002), Journal of Law and Economics 44 (3), 691-723.
“Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did it Matter to Bank Lending?" with Allen N. Berger and Joseph M. Scalise in Prudential Supervision: What Works and What Doesn't, edited by Frederic Mishkin (Chicago: University of Chicago Press, 2001).